[Veno-lymphatic insufficiency. 4,729 patients undergoing hormonal and procyanidol oligomer therapy].
Henriet
J P
JP
D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D044946:Biflavonoids; D002392:Catechin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003278:Contraceptives, Oral, Hormonal / Q000008:administration & dosage / Q000009:adverse effects*; D004361:Drug Tolerance; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D004967:Estrogens / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005419:Flavonoids / Q000627:therapeutic use; D006801:Humans; D007866:Leg / Q000098:blood supply; D008206:Lymphatic Diseases / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D008875:Middle Aged; D044945:Proanthocyanidins; D011374:Progesterone / Q000008:administration & dosage / Q000009:adverse effects; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D014689:Venous Insufficiency / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology
D000959:Antihypertensive Agents; D044946:Biflavonoids; D003278:Contraceptives, Oral, Hormonal; D004967:Estrogens; D005419:Flavonoids; D044945:Proanthocyanidins; C017674:procyanidin; D011374:Progesterone; D002392:Catechin
Insuffisance veino-lymphatique. 4,729 patientes sous thérapeutique hormonale et oligomeres procyanidoliques.